These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 26159742)

  • 61. Management of the Patient With HIV/Hepatitis C Drug Interactions: A Guide for Nurses and Nurse Practitioners.
    Starbird LE; Hong H; Sulkowski MS; Farley JE
    J Assoc Nurses AIDS Care; 2020; 31(2):241-248. PubMed ID: 31855873
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Efficacy and safety of pegylated-interferon plus ribavirin in HIV-infected patients co-infected with hepatitis C virus in clinical practice: a 32 cases observational follow-up].
    Seydi M; Morlat P; Bonnet F; Rambeloarisoa J; Bernard N; Lacoste D; Bonarek M; Trimoulet P; Ramanampamonjy R; Lafon ME; Dramé M; Beylot J
    Rev Med Interne; 2005 Apr; 26(4):280-7. PubMed ID: 15820563
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Treatment of hepatitis C in HIV-coinfected patients.
    Hughes CA; Shafran SD
    Ann Pharmacother; 2006 Mar; 40(3):479-89; quiz 582-3. PubMed ID: 16507622
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Drug Interactions With Direct-Acting Antivirals for Hepatitis C: Implications for HIV and Transplant Patients.
    Burgess S; Partovi N; Yoshida EM; Erb SR; Azalgara VM; Hussaini T
    Ann Pharmacother; 2015 Jun; 49(6):674-87. PubMed ID: 25770114
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Management of Hepatitis C/HIV Coinfection in the Era of Highly Effective Hepatitis C Virus Direct-Acting Antiviral Therapy.
    Wyles DL; Sulkowski MS; Dieterich D
    Clin Infect Dis; 2016 Jul; 63 Suppl 1(Suppl 1):S3-S11. PubMed ID: 27363438
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort.
    d'Arminio Monforte A; Cozzi-Lepri A; Ceccherini-Silberstein F; De Luca A; Lo Caputo S; Castagna A; Mussini C; Cingolani A; Tavelli A; Shanyinde M; Gori A; Girardi E; Andreoni M; Antinori A; Puoti M;
    PLoS One; 2017; 12(5):e0177402. PubMed ID: 28520749
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Focus on drug interactions: the challenge of treating hepatitis C virus infection with direct-acting antiviral drugs in the HIV-positive patient.
    Rodríguez-Torres M
    Curr Opin Infect Dis; 2013 Feb; 26(1):50-7. PubMed ID: 23242341
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Interferon-free therapy in hepatitis C virus (HCV) monoinfected and HCV/HIV coinfected patients: effect on cognitive function, fatigue, and mental health.
    Kleefeld F; Heller S; Ingiliz P; Jessen H; Petersen A; Kopp U; Kraft A; Hahn K
    J Neurovirol; 2018 Oct; 24(5):557-569. PubMed ID: 29785584
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A case of successful hepatitis C virus eradication by 24 weeks of telaprevir-based triple therapy for a hemophilia patient with hepatitis C virus/human immunodeficiency virus co-infection who previously failed pegylated interferon-α and ribavirin therapy.
    Murata M; Furusyo N; Ogawa E; Mitsumoto F; Hiramine S; Ikezaki H; Takayama K; Shimizu M; Toyoda K; Kainuma M; Hayashi J
    J Infect Chemother; 2014 May; 20(5):320-4. PubMed ID: 24477330
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Preemptive antiretroviral therapy modifications for the management of potential clinically significant drug interactions with direct acting hepatitis C therapies.
    Stambough M; Roman M; Blair DC; Sidman EF; Miller CD
    Int J STD AIDS; 2016 Mar; 27(3):235-7. PubMed ID: 25824150
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients.
    Dominguez S; Ghosn J; Valantin MA; Schruniger A; Simon A; Bonnard P; Caumes E; Pialoux G; Benhamou Y; Thibault V; Katlama C
    AIDS; 2006 May; 20(8):1157-61. PubMed ID: 16691067
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Positive impact of hepatitis C virus (HCV) treatment on antiretroviral treatment adherence in human immunodeficiency virus-HCV coinfected patients: one more argument for expanded access to HCV treatment for injecting drug users.
    Roux P; Fugon L; Winnock M; Salmon-Céron D; Lacombe K; Sogni P; Spire B; Dabis F; Carrieri MP;
    Addiction; 2012 Jan; 107(1):152-9. PubMed ID: 21819472
    [TBL] [Abstract][Full Text] [Related]  

  • 73. HIV and hepatitis C coinfection.
    Matthews GV; Dore GJ
    J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 1):1000-8. PubMed ID: 18707597
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Response to direct-acting antivirals for hepatitis C treatment in vertically HIV/HCV co-infected patients.
    Carrasco I; Sainz T; Frick MA; Jiménez de Ory S; Fortuny C; Burgos J; Montero M; Gavilán C; Falcón MD; Couceiro JA; Bernardino JI; Bisbal O; Guerrero C; Aldámiz-Echevarría MT; Berenguer J; Navarro ML;
    J Viral Hepat; 2020 Sep; 27(9):955-958. PubMed ID: 32347645
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Treatment of hepatitis C in patients infected with human immunodeficiency virus in the direct-acting antiviral era.
    Soriano V; Labarga P; Vispo E; Fernández-Montero JV; Barreiro P
    Infect Dis Clin North Am; 2012 Dec; 26(4):931-48. PubMed ID: 23083825
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Effect of an induction period of pegylated interferon-α2a and ribavirin on early virological response in HIV-HCV-coinfected patients: results from the CORAL-2 study.
    Tural C; Solà R; Alvarez NP; Moltó J; Sánchez M; Zamora AM; Ornelas A; Laguno M; González J; von Wichmann MÁ; Téllez MJ; Paredes R; Clotet B;
    Antivir Ther; 2011; 16(6):833-41. PubMed ID: 21900715
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Direct-acting antivirals for hepatitis C virus infections in patients co-infected with human immunodeficiency virus.
    Piroth L
    Clin Res Hepatol Gastroenterol; 2011 Dec; 35 Suppl 2():S75-83. PubMed ID: 22248699
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study.
    Molina JM; Orkin C; Iser DM; Zamora FX; Nelson M; Stephan C; Massetto B; Gaggar A; Ni L; Svarovskaia E; Brainard D; Subramanian GM; McHutchison JG; Puoti M; Rockstroh JK;
    Lancet; 2015 Mar; 385(9973):1098-106. PubMed ID: 25659285
    [TBL] [Abstract][Full Text] [Related]  

  • 79. How Generalizable Are the Results From Trials of Direct Antiviral Agents to People Coinfected With HIV/HCV in the Real World?
    Saeed S; Strumpf EC; Walmsley SL; Rollet-Kurhajec K; Pick N; Martel-Laferrière V; Hull M; Gill MJ; Cox J; Cooper C; Klein MB; ; Cohen J; Conway B; Cooper C; Côté P; Cox J; Gill J; Haider S; Harris M; Haase D; Hull M; Montaner J; Moodie E; Pick N; Rachlis A; Rouleau D; Sandre R; Tyndall JM; Vachon ML; Walmsley S; Wong D
    Clin Infect Dis; 2016 Apr; 62(7):919-926. PubMed ID: 26743093
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Coinfection with hepatitis C virus and HIV].
    Ruys TA; Reesink HW; Lange JM
    Ned Tijdschr Geneeskd; 2003 Oct; 147(42):2056-60. PubMed ID: 14606352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.